Search

Your search keyword '"Protein Serine-Threonine Kinases antagonists & inhibitors"' showing total 7,826 results

Search Constraints

Start Over You searched for: Descriptor "Protein Serine-Threonine Kinases antagonists & inhibitors" Remove constraint Descriptor: "Protein Serine-Threonine Kinases antagonists & inhibitors"
7,826 results on '"Protein Serine-Threonine Kinases antagonists & inhibitors"'

Search Results

1. Targeting Protein Kinase, Membrane-Associated Tyrosine/Threonine 1 (PKMYT1) for Precision Cancer Therapy: From Discovery to Clinical Trial.

2. Novel Dichloroacetophenone-Based PDHK1 Inhibitors as Potent Anticancer Agents.

3. Tribbles pseudokinase 3 promoted renal fibrosis by regulating the expression of DNA damage-inducible transcript 3 in diabetic nephropathy.

4. Capturing Autoinhibited PDK1 Reveals the Linker's Regulatory Role, Informing Innovative Inhibitor Design.

5. In Silico Insights: QSAR Modeling of TBK1 Kinase Inhibitors for Enhanced Drug Discovery.

6. Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B.

7. Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.

8. Strategies that regulate Hippo signaling pathway for novel anticancer therapeutics.

9. Serum and glucocorticoid-regulated kinase 1 (SGK1) as an emerging therapeutic target for cardiac diseases.

10. Insulin-degrading enzyme inhibition increases the unfolded protein response and favours lipid accumulation in the liver.

11. CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1.

12. LATS1 inhibitor and zinc supplement synergistically ameliorates contrast-induced acute kidney injury: Induction of Metallothionein-1 and suppression of tubular ferroptosis.

13. Commentary on "Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis".

14. Design, synthesis, and biological evaluation of β-carboline-cinnamic acid derivatives as DYRK1A inhibitors in the treatment of diabetes.

15. IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells.

16. Correspondence: Reply to commentary on "Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis".

17. TNIK in disease: from molecular insights to therapeutic prospects.

18. AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer.

19. Design and evaluation of novel inhibitors for the treatment of clear cell renal cell carcinoma.

20. A novel approach to investigate the combinatorial effects of TLK1 (Tousled-Like Kinase1) inhibitors with Temozolomide for glioblastoma therapy.

21. Targeting polo-like kinase 1: advancements and future directions in anti-cancer drug discovery.

22. Selective and effective suppression of pancreatic cancer through MNK inhibition.

23. SRPK Inhibitors Reduce the Phosphorylation and Translocation of SR Protein Splicing Factors, thereby Correcting BIN1 , MCL-1 and BCL2 Splicing Errors and Enabling Apoptosis of Cholangiocarcinoma Cells.

24. Inactivation of HIPK2 attenuates KRAS G12D activity and prevents pancreatic tumorigenesis.

25. GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model.

26. Synthesis and evaluation of isothiazolo[4,5- b ]pyridines as cyclin G-associated kinase (GAK) inhibitors.

27. A novel PDHK inhibitor restored cognitive dysfunction and limited neurodegeneration without affecting amyloid pathology in 5xFAD mouse, a model of Alzheimer's disease.

28. Inhibition of Aberrantly Overexpressed Polo-like Kinase 4 Is a Potential Effective Treatment for DNA Damage Repair-Deficient Uterine Leiomyosarcoma.

29. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.

30. Virtual screening of natural products to enhance melanogenosis.

31. Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis.

32. Design and synthesis of novel fluorene derivatives as inhibitors of pyruvate dehydrogenase kinase.

33. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).

34. Inhibition of ULK1/2 and KRAS G12C controls tumor growth in preclinical models of lung cancer.

35. GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer.

36. Comments on 'Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer'.

37. Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy.

39. Regulated induced proximity targeting chimeras-RIPTACs-A heterobifunctional small molecule strategy for cancer selective therapies.

40. Diverse functions of Tribbles homolog 3 in cancers and its potential as a therapeutic target.

41. PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma.

42. Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease.

43. A Comprehensive In Vitro Characterization of a New Class of Indole-Based Compounds Developed as Selective Haspin Inhibitors.

44. Identification of potential PIM-2 inhibitors via ligand-based generative models, molecular docking and molecular dynamics simulations.

45. A polo-like kinase 1 inhibitor enhances erastin sensitivity in head and neck squamous cell carcinoma cells in vitro.

46. Discovery of a dual-target DYRK2 and HDAC8 inhibitor for the treatment of hepatocellular carcinoma.

47. Design and synthesis of novel thiazole-derivatives as potent ALK5 inhibitors.

48. Energy‑stress‑mediated activation of AMPK sensitizes MPS1 kinase inhibition in triple‑negative breast cancer.

49. Click-chemistry mediated synthesis of OTBN-1,2,3-Triazole derivatives exhibiting STK33 inhibition with diverse anti-cancer activities.

50. TRIB2-Mediated Modulation of AMPK Promotes Hepatic Insulin Resistance.

Catalog

Books, media, physical & digital resources